Thiotepa, Tepadina(thiotepa)
Tepadina, Tepylute, Thiotepa (thiotepa) is a small molecule pharmaceutical. Thiotepa was first approved as Thiotepa on 1982-01-01. It is used to treat adenocarcinoma, breast neoplasms, lymphoma, ovarian neoplasms, and sarcoma amongst others in the USA. It has been approved in Europe to treat hematopoietic stem cell transplantation and neoplasms. It is known to target cytochrome P450 2B6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Tepadina, Tepylute, Thiotepa (discontinued: Thioplex, Thiotepa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Thiotepa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TEPADINA | Adienne | N-208264 RX | 2017-01-26 | 2 products, RLD, RS |
| TEPYLUTE | Shorla Pharma | N-216984 RX | 2024-06-25 | 2 products, RLD, RS |
Show 2 discontinued
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| breast neoplasms | EFO_0003869 | D001943 | C50 |
| ovarian neoplasms | EFO_0003893 | D010051 | C56 |
| sarcoma | — | D012509 | — |
| lymphoma | — | D008223 | C85.9 |
| urinary bladder neoplasms | — | D001749 | C67 |
| adenocarcinoma | — | D000230 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
THIOTEPA, TEPADINA, ADIENNE SA | |||
| 2024-01-26 | ODE-129 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9340 | Injection, thiotepa, 15 mg |
Clinical
Clinical Trials
315 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Thiotepa |
| INN | thiotepa |
| Description | Thiotepa is a member of aziridines. |
| Classification | Small molecule |
| Drug class | antineoplastics (thiotepa derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | S=P(N1CC1)(N1CC1)N1CC1 |
Identifiers
| PDB | — |
| CAS-ID | 52-24-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL671 |
| ChEBI ID | 9570 |
| PubChem CID | 5453 |
| DrugBank | DB04572 |
| UNII ID | 905Z5W3GKH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP2B6
CYP2B6
Organism
Homo sapiens
Gene name
CYP2B6
Gene synonyms
NCBI Gene ID
Protein name
cytochrome P450 2B6
Protein synonyms
1,4-cineole 2-exo-monooxygenase, CYPIIB6, Cytochrome P450 IIB1, cytochrome P450, family 2, subfamily B, polypeptide 6, cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,469 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tepadina, Tepylute, Thiotepa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,937 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use